Evidence map›Paper›PMID 26511266›Full record

Trial reportAnnals of surgical oncology2016

Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.

Yuka Asano, Shinichiro Kashiwagi, Naoyoshi Onoda, Satoru Noda, Hidemi Kawajiri, Tsutomu Takashima, Masahiko Ohsawa, Seiichi Kitagawa, Kosei Hirakawa

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Inflammation-related biomarkers as predictors of pathological complete response in early-stage breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuka AsanoDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Shinichiro KashiwagiDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan. spqv9ke9@view.ocn.ne.jp.
Naoyoshi OnodaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Satoru NodaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Hidemi KawajiriDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Tsutomu TakashimaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Masahiko OhsawaDepartment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Seiichi KitagawaDepartment of Physiology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Kosei HirakawaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe neutrophil/lymphocyte ratio (NLR) has been reportedly associated with prognosis in cancer patients by influencing both cancer progression and chemosensitivity. However, the correlation between NLR and the outcome of neoadjuvant chemotherapy (NAC) in breast cancer patients remains unclear.

methodsNLR was evaluated in 177 patients with breast cancer treated with NAC with 5-fluorouracil, epirubicin, and cyclophosphamide, followed by weekly paclitaxel and subsequent curative surgery. The correlation between NLR and prognosis, including the efficacy of NAC, was evaluated retrospectively.

resultsNLR ranged from 0.5 to 10.6. Fifty-eight patients with low NLR (<3.0) had a higher pathological complete response (pCR) rate (p < 0.001) and were more frequently diagnosed with ER-negative/progesterone receptor (PR)-negative/HER2-negative (triple-negative) breast cancer (TNBC; p < 0.001) compared with patients with high NLR (≥3.0). Among TNBC patients who achieved pCR, disease-free survival (p = 0.006) and overall survival (p < 0.001) were significantly longer in patients with low NLR than in those with high NLR. Low NLR was associated with a significantly favorable prognosis in TNBC patients who achieved pCR, according to univariate analysis (p = 0.044, hazard ratio = 0.06).

conclusionsLow NLR may indicate high efficacy and favorable outcome after NAC in patients with TNBC.

Indexed as

Neoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCyclophosphamideEpirubicinErb-b2 Receptor Tyrosine KinasesFemaleFluorouracilFollow-Up StudiesHumansImmunoenzyme TechniquesLymphocytesMiddle AgedNeoplasm StagingNeutrophilsPaclitaxelBiomarkers, TumorCyclophosphamideEpirubicinErb-b2 Receptor Tyrosine KinasesFluorouracilPaclitaxelReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID26511266
PMCPMC4773470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.